Advances in treatments for Sjogren's syndrome: CmseMark the glass is half full
- 1 September 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet Rheumatology
- Vol. 2 (9), E516-E518
- https://doi.org/10.1016/S2665-9913(20)30220-4
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trialThe Lancet Rheumatology, 2020
- Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)The Lancet Rheumatology, 2020
- Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyThe Lancet Rheumatology, 2020
- The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trialsAutoimmunity Reviews, 2019
- Primary Sjögren’s SyndromeNew England Journal of Medicine, 2018
- Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren SyndromeJAMA, 2014
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot studyAnnals Of The Rheumatic Diseases, 2007